ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+10.81%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$7.37B
AUM Growth
+$7.37B
(+9.4%)
Cap. Flow
+$320M
Cap. Flow
% of AUM
4.34%
Top 10 Holdings %
Top 10 Hldgs %
69.13%
Holding
45
New
6
Increased
11
Reduced
7
Closed
1
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$112M |
| 2 |
Krystal Biotech
KRYS
|
$95.2M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
$88M |
| 4 |
Roivant Sciences
ROIV
|
$58.5M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$49.2M |
Top Sells
| 1 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$81.3M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$35M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
$13.9M |
| 4 |
Nuvalent
NUVL
|
$12.2M |
| 5 |
argenx
ARGX
|
$9.35M |
Sector Composition
| 1 | Healthcare | 99.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $1.01B | 13.73% | 11,111,111 | – | – |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $720M | 9.77% | 7,000,000 | – | – |
|
3
United Therapeutics
UTHR
$13.8B
| $642M | 8.71% | 2,909,999 +39,999 | +1% | +$8.83M |
|
|
4
Sarepta Therapeutics
SRPT
$1.78B
| $530M | 7.19% | 4,627,888 +977,888 | +27% | +$112M |
|
|
5
argenx
ARGX
$43.6B
| $492M | 6.68% | 1,263,500 -24,000 | -2% | -$9.35M |
|
|
6
Madrigal Pharmaceuticals
MDGL
$9.76B
| $350M | 4.75% | 1,515,151 -151,515 | -9% | -$35M |
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $347M | 4.7% | 4,000,000 +55,000 | +1% | +$4.77M |
|
8
Amicus Therapeutics
FOLD
$2.34B
| $344M | 4.67% | 27,400,000 +100,000 | +0.4% | +$1.26M |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $339M | 4.59% | 1,759,606 -42,300 | -2% | -$8.14M |
|
10
Ascendis Pharma
ASND
$11.8B
| $320M | 4.34% | 3,580,555 +255,555 | +8% | +$22.8M |
|
|
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $317M | 4.3% | 8,050,000 +1,250,000 | +18% | +$49.2M |
|
|
12
Krystal Biotech
KRYS
$4.27B
| $301M | 4.08% | 2,560,811 +810,811 | +46% | +$95.2M |
|
13
Alnylam Pharmaceuticals
ALNY
$58.5B
| $210M | 2.85% | 1,105,000 | – | – |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $201M | 2.72% | 5,555,555 | – | – |
|
15
Xenon Pharmaceuticals
XENE
$2.98B
| $189M | 2.56% | 4,900,000 | – | – |
|
|
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
| $113M | 1.53% | 10,300,000 | – | – |
|
|
DICE
17
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $102M | 1.39% | 2,199,342 -1,750,658 | -44% | -$81.3M |
|
18
Kymera Therapeutics
KYMR
$2.95B
| $88.6M | 1.2% | 3,855,000 | – | – |
|
|
19
MoonLake Immunotherapeutics
MLTX
$3.54B
| $88M | 1.19% | +1,725,000 | New | +$88M |
|
20
BioCryst Pharmaceuticals
BCRX
$1.74B
| $84.9M | 1.15% | 12,055,000 +1,635,000 | +16% | +$11.5M |
|
|
21
Nuvalent
NUVL
$5.52B
| $67.5M | 0.92% | 1,600,000 -288,888 | -15% | -$12.2M |
|
|
22
Roivant Sciences
ROIV
$8.15B
| $58.5M | 0.79% | +5,806,162 | New | +$58.5M |
|
23
Syndax Pharmaceuticals
SNDX
$1.41B
| $55.5M | 0.75% | 2,650,000 | – | – |
|
24
Iovance Biotherapeutics
IOVA
$807M
| $47.2M | 0.64% | 6,700,000 -320,000 | -5% | -$2.25M |
|
25
MannKind Corp
MNKD
$1.41B
| $37M | 0.5% | 9,100,000 | – | – |
|